Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2023-03-15
Target enrollment:
Participant gender:
Summary
After progression of disease after one chemotherapy, metastatic breast cancer patients will
be randomized 1:1 to one of the following treatment arms:
Arm A. Eribulin Arm B. Paclitaxel
Blood draws for immune analysis will be performed before start of therapy, on day 1 of cycle
2 and on day 21 of cycle 4 (end of therapy) for the primary study aim. Patients will be
treated under study conditions for a maximum of 4 therapy cycles.